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OBJECTIVE: This is a health economic evaluation of the long
acting insulin analogue, insulin detemir (IDet) when type 2 dia-
betes patients are switched from either oral antidiabetics (OAD)
or from neutral protamine Hagedorn (NPH) insulin. The data
used as clinical input for the analysis was the Austrian sub-
population of the large observational trial, PREDICTIVE.
METHODS: A published validated diabetes model was used to
estimate the long-term cumulative incidence of complications,
life expectancy (LE), quality-adjusted life expectancy (QALE)
and lifetime costs when switching to IDet from OADs or NPH.
The outcomes were modeled based on the clinical ﬁndings and
validated Austrian costs and treatment patterns. The analysis
used the-third party health care payer perspective. Future costs
and clinical beneﬁts were discounted at 5% per annum.
RESULTS: Conversion to insulin detemir was projected to
improve life expectancy by 0.624 years when switching from
OADs and 0.201 years from NPH. Quality-adjusted life years
(QALYs) increased by 0.52 versus OADs and 0.368 versus NPH.
Direct medical costs over patient lifetimes were projected to be
increased by €5585 compared to OAD-treatment and €2206
versus NPH treatment. Thus, incremental cost-effectiveness
ratios of IDet versus OAD and NPH treatment were €10,739
and €5,996, respectively. Estimates were controlled by multiple
sensitivity analyses and were found to be robust. Probabilistic
sensitivity analyses showed that the cost-effectiveness acceptabil-
ity percentages with a threshold of €30,000 were 100% for
OAD switch and 99.9% for NPH switches. CONCLUSION:
Short-term improvements seen when switching to IDet from
OADs or NPH were projected to show improvements in quality-
adjusted life expectancy with a cost-effectiveness ratio which fell
well within the range usually considered acceptable value for
money.
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OBJECTIVE: A pooled analysis of three clinical trials showed
the therapy beneﬁts of treating type 1 diabetic patients (mean age
40.3 years, duration of diabetes 16.3 years, HbA1c 8.3%, BMI
25.2 kg.m-2) with insulin detemir (IDet) versus neutral protamine
Hagedorn (NPH) insulin as the basal component of basal-bolus
therapy when used in combination with either insulin aspart
(IAsp) or human soluble insulin (HSI). The analysis demon-
strated a short-term improvement for detemir over NPH in
HbA1c (0.13% points lower), a decrease in hypoglycemic events
(by 4%) and lower body mass index (BMI) (0.21 kg.m-2).
METHODS: A published validated diabetes model was used to
estimate the long-term cumulative incidence of complications,
life expectancy (LE), quality-adjusted life expectancy (QALE)
and lifetime costs for IDet versus NPH regimens. Treatment
pattern and costs in the Portuguese setting were taken from
published sources and validated with clinical experts. All out-
comes were discounted at 5% annually. RESULTS: The IDet arm
was associated with an increase in life expectancy, compared to
NPH, of 0.062 years with a resulting gain in QALE of 0.184
quality-adjusted life years, QALYs (SD) (6.3  0.06 versus
6.12  0.06 QALYs) due to a reduction in diabetes-related com-
plications. Increased treatment costs for IDet resulted in greater
total lifetime costs per patient than with NPH (€37,760  743
versus €33,403  738), leading to an incremental cost-
effectiveness ratio of €23,691 per QALY gained. The results were
robust when tested for parameter sensitivity. Cost-effectiveness
acceptability with a threshold of €50,000 is 90%. CONCLU-
SION: Short-term improvements seen with IDet versus NPH in
basal-bolus therapy were projected to show improvements in
quality-adjusted life expectancy with a cost-effectiveness ratio
which fell well within the range usually considered acceptable
value for money.
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OBJECTIVE: To compare medical costs between long term
somatostatin analogs, lanreotide Autogel and octreotide LAR in
the treatment of patients with Acromegaly, from an institutional
perspective. METHODS: Cost-effectiveness analysis using a deci-
sion tree model that simulates the cost and efﬁcacy of the treat-
ment of acromegaly with long term somatostatin analogs, for a
temporary horizon of 15 months was conducted. The effective-
ness measure was the percentage of patients achieving a reduc-
tion in IGF-1 and growth hormone levels, obtained from clinical
trials published in international literature. The average dose used
in the analysis was 96.9 for lanreotide Autogel and 26.4 for
octreotide LAR. Only direct medical costs were considered in the
analysis. Costs were estimated using 2007 prices and are
expressed in United States dollars (exchange rate of 10.93 pesos
per US dollar). RESULTS: The treatment with lanreotide Autogel
showed the best average cost per acromegalic patient treated
with $21,645.60, followed by the treatment with octreotide LAR
with a cost of $24,614.40. Thirty percent of patients achieved a
reduction of IGF-1 and growth hormone to safe levels with both
treatments. Thus, the treatment with lanreotide Autogel had the
lowest cost per successfully treated patient: $72,151.90; followed
by the treatment with octreotide LAR with a cost of $82,047.80.
The univariate and probabilistic sensitivity analysis both showed
that results of the base analysis do not change, provided that the
price ratio of comparators is less than 1.18. CONCLUSION: The
percentage of patients achieving normal IGF-1 and growth levels
is similar for both treatments. Lanreotide Autogel is the treat-
ment associated with a lower drug cost in the Mexican context.
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OBJECTIVES: Premixed and preﬁlled disposable devices are now
available to administer liquid Human Growth Hormone (hGH).
The study objective was to conduct a Cost Minimization Analysis
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(CMA) based on Time-and-Motion (TM) simulations designed to
allow comparison of the complexity related to hGH preparation
and administration. METHODS: Nurses naïve to hGH adminis-
tration or similar drug-device combinations were recruited to
evaluate four hGH pen devices via TM simulations. Five video-
taped and timed trials for each product were evaluated based on
four phases: 1) Learning (initial instructions for use); 2) Prepara-
tion (arranging device for use); 3) Administration (actual injec-
tion); and 4) Storage (provide for product viability between
doses). The CMA applied costs related to parental opportunity
costs categorized as wages (U.S. Bureau of Labor Statistics aver-
ages), drugs (First Databank WAC prices), and injection supplies.
RESULTS: Two pen devices (Norditropin NordiFlex NNF, Nor-
ditropin NordiPen NNP) take less Total Time (<) to use than the
comparators (Genotropin GTP < Humatrope PenHTP, p < 0.05).
Most time savings were directly related to differences in Learning
(p < 0.05) and Preparation times (p < 0.05). Between the four
hGH devices, the NNF/NNP pens appeared easier to learn to use
than the HTP/GTP pen devices (NNF = NNP < HTP < GTP,
p < 0.05) and were also easier to prepare for use (GTP < HTP,
p < 0.05). User “learning curve” slopes decreased with practice
(p < 0.05) over the ﬁve trials. Once any product was prepared for
use, Administration and Storage times were nearly identical
(p > 0.05). Parental time cost (opportunity cost) savings were
greater in devices that were easier to Learn and Prepare for use
(NNF 16% < NNP 24% < GTP 7% < HTP). Supplies costs were
<1% of drug costs for all devices. CONCLUSIONS: Simulation-
generated data demonstrated the value of multi-dimensional
product-device analysis and revealed thatNNF andNNP took less
Total Time vs. comparators.
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OBJECTIVE: To assess differences in overall and diabetes-related
cost and utilization between diabetes patients treated with insulin
detemir and insulin glargine. METHODS: Retrospective data
analysis included commercial enrollees in a large US health plan
with medical and pharmacy beneﬁts. Patients were identiﬁed if
their ﬁrst prescription claim (index) for insulin detemir or insulin
glargine occurred between May 1, 2006 and December 31, 2006.
Eligible patients were required to have 6 months of continuous
enrollment pre- and post-index date, no evidence of insulin
detemir or insulin glargine use during pre-index and an A1C
reading during the pre-index period. Primary outcomes include
daily average consumption (DACON) of insulin detemir or
insulin glargine and overall and diabetes-related cost. Differences
in outcomes between insulin detemir and insulin glargine users
were adjusted for baseline characteristics through generalized
linear modeling (GLM). Propensity score matching was used to
reduce selection bias between the two groups. RESULTS: There
were 153 insulin detemir and 640 insulin glargine patients in the
study, with no signiﬁcant difference in age, gender and diabetes
types between the two groups. Adjusted DACON for insulin
detemir users was 34.3 units/day compared to 32.9 units/day for
insulin glargine (p = 0.51). Adjusted diabetes-related pharmacy
cost for insulin detemir users was higher than insulin glargine
patients ($1467 vs. $1255; p < 0.01). However, adjusted
diabetes-related medical cost for insulin glargine users was more
than twice that of insulin detemir users ($2304 vs. $1091;
p < 0.01). Moreover, adjusted overall medical cost for insulin
glargine users was also much higher compared to insulin detemir
patients ($7497 vs. $6221; p < 0.05). No difference in overall
pharmacy cost was observed. CONCLUSION: No signiﬁcant
difference in DACON between insulin detemir and insulin
glargine users was observed. Although insulin detemir patients
pay more for diabetes-related prescription medications, these
costs were more than offset by signiﬁcantly lower diabetes-
related and overall medical costs.
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OBJECTIVE: To examine medical conditions associated with
diabetic neuropathy (DN) and to identify drivers of health care
charges and utilization using administrative claims database.
METHODS: We studied commercially-insured individuals aged
18–64 with 24 months continuous enrollment in a national
health plan. DN patients were identiﬁed by having1 claim with
a DN diagnosis between July 2004 and June 2005. Using pro-
pensity scoring, we selected a demographically-matched control
cohort of patients with diabetes (10:1 ratio to DN). We com-
pared disease prevalence, Year 2 distribution of charges, and
reasons for ER visits and inpatient admissions between DN
patients and controls. Logistic regression was used to assess the
marginal contribution of DN to the most common reasons for
ER and inpatient admissions controlling for differences in overall
illness burden. RESULTS: Compared with controls (n = 86,550),
DN patients (n = 8655) had more unique number of co-morbid
medical conditions (9.7 vs. 6.8) and higher ($41,394 vs.
$16,983) total medical charges. Both groups had the highest
medical charges for inpatient services, followed by outpatient
hospital and pharmacy use. Compared with controls, more DN
patients had ER visits (13% vs. 9%), inpatient hospital encoun-
ters (28% vs. 13%), and longer hospitalizations (2.4 vs. 0.6
days). The top ﬁve reasons for ER visits were the same for both
groups, with nonspeciﬁc backache being the most common.
Three of the top ﬁve reasons for inpatient admissions were also
the same: coronary atherosclerosis and other chronic ischemic
heart disease, chest pain, and cellulitis. Controlling for excess
illness burden, DN patients were still at a higher risk for hospi-
talizations due to chest pain, heart failure, and cellulitis.
CONCLUSION: DN patients had signiﬁcantly more co-morbid
medical conditions, ER visits, inpatient admissions, and longer
hospitalizations than age-and-sex matched controls.
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OBJECTIVE:To examine health care expenditures and utilization
among gout patients by severity of renal disease. METHODS: A
retrospective claims analysis using commercial enrollees in a U.S.
health plan age 18, treated with pharmaceuticals for incident
gout between Janaury 1, 2002 and December 31, 2005, without
cancer. Annual health service costs and utilization were compared
by severity of renal disease (using a claims-based algorithm) with
descriptive analysis and generalized linear modeling (GLM).
RESULTS: Renal disease was evident in 745 (9%) of 8039 sub-
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